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Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by mutations 
of the SERPING1 or the Factor 12 genes. It is potentially fatal, particularly if not identified 
at an early stage. Apart from androgens, which are contraindicated in children and in 
pregnant women, a range of effective, albeit very expensive treatments have recently 
become available for HAE patients. The cost of these new treatments is beyond the 
reach of most developing countries. At this time, there is no cure for the disorder. In spite 
of mutations of the SERPING1 gene, autoimmunity and infections are not prominent 
features of the condition. Here, we present the argument that HAE should be viewed 
primarily as a metabolic liver disorder. This conceptual paradigm shift will stimulate basic 
research and may facilitate new therapeutic approaches to HAE outlined in this paper. 
We suggest several novel potential treatment options for HAE from the perspectives of 
clinical immunology, molecular biology, and liver transplantation. Many of these offer the 
prospect of curing the disorder. The effectiveness of these options is rapidly improving 
in many cases, and their risks are decreasing. Given the very high costs of treating HAE, 
some of these curative options may become feasible in the next decade.
Keywords: hereditary angioedema types i and ii, gene therapy, crisPr/cas9, liver, metabolic diseases
iNtrODUctiON
Hereditary angioedema (HAE) is rare disorder caused by mutations of the SERPING1 or F12 genes. 
It was first described by Quincke in 1882 (1) and subsequently by Osler (2). Affected patients experi-
ence recurrent abdominal pain or swelling, which can be fatal if it involves the larynx. Current 
estimates suggest a prevalence of about 1:70,000 in the general population (3). There is no obvious 
ethnic variation in the disorder. Typically, symptoms begin in late childhood and become worse after 
puberty. Therefore, the disorder has a much higher morbidity and mortality in adults compared with 
children.
Hereditary angioedema is an autosomal dominant disorder, where heterozygotes are sympto-
matic. There are examples of variable penetrance and expressivity of the gene, where some affected 
family members may not manifest any symptoms. As discussed below, there are recent data suggest-
ing sequence variations in genes involved in the production or catabolism of bradykinin might also 
tAbLe 1 | comparison of currently available treatments for HAe types 1 and 2.
current treatment cost/
year
benefits risks comment
Fibrinolytic inhibitors Cheap Cheap Risk of thrombosis in pregnancy. Partially effective Can be used in children who 
develop HAE symptoms early
Androgens Cheap Cheap Contraindicated in pregnancy, children. Hepatic adenomas, 
lipids
Virilizing adverse effects in females
C1 inhibitor prophylaxis High Effective Risk of pathogen transmission (not with recombinant C1 INH) Unaffordable for most countries
Bradykinin receptor 
antagonists
High Effective for acute attacks Pain at local site Unaffordable for most countries
Kallekrein inhibitors High Potential for oral treatment Systemic reactions for parenteral preparations Unaffordable for most countries
The costs for these medicines vary in different countries.
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influence the severity of the disorder. This phenotypic variability 
can contribute to the delay in diagnosis of the condition, which 
is typically about 8 years (4, 5). There is a high mortality rate in 
HAE patients prior to diagnosis (6).
Angioedema attacks can be triggered by trauma, stress, and 
hormonal changes associated with menstruation or pregnancy in 
affected women. There is evidence for systemic effects of local 
activation of the contact phase (7). Estrogens and angiotensin-
converting enzyme (ACE) inhibitors can also trigger attacks, the 
latter by interfering with metabolism of bradykinin. ACE is the 
dominant enzyme responsible for degrading bradykinin.
It is clear that androgen treatment can reduce the frequency 
and severity of the attacks (8). However, androgens are con-
traindicated in children and pregnant women and can cause 
troublesome virilizing adverse effects in women (8). In the last 
few years, there have been remarkable advances in management 
of the disorder (9). Use of purified or recombinant C1 inhibi-
tor (C1 INH) is effective in treating severe attacks, especially if 
administered early. Other drugs, such as bradykinin receptor, 
antagonists, and kallikrein inhibitors, have also proven to be 
effective in treating acute attacks (10). Unfortunately, the high 
cost of these newer medications places them beyond the reach of 
most developing countries (Table 1). In spite of these advances, a 
cure for this potentially fatal disorder has been elusive.
Recurrent infections or autoimmunity are not a feature of 
the disorder. Yet, in the most recent IUIS/WHO classification 
of primary immunodeficiency disorders, HAE is listed as an 
immunodeficiency disorder because the mutated gene functions 
as an inhibitor of the complement cascade (11). The dominant 
biochemical problem is impaired function of the contact phase 
leading to unregulated production of bradykinin (12), which in 
turn causes the angioedema. Although useful for making the diag-
nosis, the complement cascade is mostly a bystander in swelling 
attacks. Dysfunction of the complement system does not lead to 
immediate symptoms or major complications in HAE. Sequence 
variations in SERPING1 have been linked to age-related macular 
degeneration (13).
Here, we present the argument that HAE should be concep-
tualized as a metabolic liver disorder. This is likely to assist with 
research, which we believe may result in a cure for our patients 
within our lifetimes. While we discuss these technologies/treat-
ments as possible alternatives to current treatment (Figure 1), it 
is essential that the risks of these approaches (Table 2; Figure 1) 
are carefully considered and technical issues are resolved before 
human trials are undertaken. The most important principle is 
primum non-nocere.
UNDerstANDiNG trANsiNHibitiON As 
A criticAL cOMPONeNt OF tHe 
MOLecULAr bAsis OF tYPe 1 HAe
A better understanding of the molecular pathology of HAE may 
result in the availability of more effective therapies for the disor-
der. It is now apparent that HAE is a genetically complex disorder. 
It belongs to the serpinopathies, as exemplified by alpha1 antri-
trypsin deficiency. In addition to mutations of the SERPING1 
gene, sequence variations in other genes such as F12, peptidases, 
and bradykinin receptors may influence the phenotypic severity 
of the disorder (14).
For the purposes of this review, we shall be focusing on type 1 
and type 2 HAE. HAE with normal C 1 INH (previously known 
as type 3 HAE) appears to have a different pathogenesis. Some of 
these patients have causative mutations of the F12 gene, while the 
pathogenesis of the disorder is unknown in other HAE patients 
(14). While some of the therapeutic options suggested here may 
be useful for F12 gene mutations also, less is known about this 
condition than types 1 and 2 HAE. In this perspective, we shall 
therefore be focusing on types 1 and 2 HAE.
Potential curative options are critically linked to the molecu-
lar biology of the disorder, particularly transinhibition. Type 
1 and type 2 HAE are caused by mutations of the SERPING1 
gene. Over 400 different mutations have been described in the 
condition (15). Given the autosomal dominant inheritance, 
affected patients have one mutated and one wild-type allele. In 
type 1 HAE, C1 INH levels are very low or absent in the blood. 
In type 2 HAE, levels of C1 INH are normal or elevated. Type 
2 HAE is thought to be a dominant-negative disorder, caused 
by a circulating dysfunctional protein, which competitively 
inhibits wild-type C1 INH. Some patients with type 2 HAE also 
produce aggregates of mutant C1 INH multimers, which have the 
potential to directly activate the contact phase, leading to further 
bradykinin production (16).
Based on the molecular pathology, patients with type 2 HAE 
might be expected to have missense mutations of the SERPING1 
gene allowing expression of a dysfunctional protein causing a 
FiGUre 1 | showing pathogenesis of HAe and treatments discussed in this article. (1) Contact phase. In HAE, an excess of bradykinin is present as a result 
of impaired C1 INH function. (2) This leads to extravasation of fluid from blood vessels (3) leading to angioedema. (4) Possible treatments discussed include liver 
transplantation (including APOLT), (5) hepatocyte transplantation, (6) liver-based gene therapy, (7) and genome editing. (8) Bone marrow transplantation has also led 
to a cure of HAE. (9) Figure constructed with clipart from Microsoft PowerPoint.
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dominant-negative effect, and patients with type 1 HAE might be 
expected to have severe mutations such as nonsense mutations or 
complex rearrangements leading to haploinsufficiency. This is not 
invariable (17). In spite of one wild-type allele, patients with type 
1 HAE may have low circulating C1 INH. In type 2 HAE patients, 
the functional C1-INH plasma levels are between 5 and 30% of 
the normal range, as opposed to the 50% as may be expected in 
heterozygotes (18). While there may be some evidence for excess 
consumption (17), there is evidence for transinhibition of the 
wild-type protein by the mutant allele in type 1 HAE (19). Gene 
expression profiling has shown that mutant as well as wild-type 
transcripts were reduced in HAE patients (20).
An important publication over 20  years ago addressed this 
observation in fibroblasts from HAE patients (19). The authors 
reported a patient with a deletion of exon 7 that allowed com-
parison of wild-type vs. mutant allele expression. It appears that 
both transcription and translation of the wild-type allele were 
impaired. A similar phenomenon was seen in HAE mice gener-
ated by gene targeting (21). There has not been further explora-
tion of this important observation. The precise mechanism of 
how transinhibition occurs in HAE has not been elucidated. The 
transinhibition of SERPING1 does not appear to influence the 
expression or production of other hepatic proteins.
It is apparent that wild-type C1 INH levels increase in HAE 
patients who have been treated with androgens. Androgens 
also appear to increase the levels of Aminopeptidase P, which in 
turn accelerates catabolism of bradykinin (22). The molecular 
mechanism for these effects has not been elucidated in  vitro. 
Understanding the molecular basis of these actions may offer 
insights into the pathogenesis of the disorder and lead to new and 
more effective treatments without the troublesome adverse effects 
of androgen therapy. It is also apparent that some cytokines such 
as IL6 can result in substantial upregulation of hepatic C1 INH 
production (23). It may be possible to design a biosimilar, which 
tAbLe 2 | Potentially curative options for patients with types 1 and 2 HAe.
Potential 
curative 
treatments
cost/year benefits risks comment
Liver 
transplantation
High initial cost and 
moderate ongoing costs
Potentially curative Peri-operative risks and long-term 
immunosuppression
Dependent on transplanted liver
APOLT High initial cost and 
moderate ongoing costs
Potentially curative Peri-operative risks and long-term 
immunosuppression
Native liver preserved so 
immunosuppression could be withdrawn 
if alternative therapies became available
Hepatocyte 
transplantation
High Minimally invasive May require immunosuppression. 
May fail over time
Experimental
AV Unacceptable risks
AAV High Allowing vector entry into hepatocytes. 
Could be used for gene editing or to 
deliver wild-type gene
Approved for FIX deficiency May need ongoing immunosuppression
Stealth viruses Very high No need for immunosuppression. 
Could be used to deliver wild-type gene
Endogenous hence less likely to be 
antigenic
Customized viral vector needed. 
Probably not practical for routine use
CRISPR Cas9 High Potential for correcting mutation Serious risk of off-target effects Unlikely to a practical option in the near 
future
The cost of liver transplantation varies in different countries.
APOLT, auxiliary partial orthotopic liver transplantation; AV, adenovirus; AAV, adeno-associated virus.
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upregulates C1 INH production, without the deleterious adverse 
effects of IL6 on B cells and other target cells.
HAe As A MetAbOLic Liver DisOrDer: 
OPtiONs FOr Liver Or HePAtOcYte 
trANsPLANtAtiON
Given that C1 INH appears to be produced predominantly in the 
liver, HAE could be considered a metabolic liver disorder (Table 2; 
Figure 1). Liver transplantation is a proven effective treatment for 
other potentially fatal metabolic liver disorders (24, 25). However, 
the procedure carries significant surgical risks and transplanted 
patients require long-term immunosuppression to prevent graft 
rejection. These drugs have a variety of adverse effects includ-
ing predisposition to infections, impaired renal function, and 
an increased risk of some malignancies. The shortage of donor 
organs also limits the availability of liver transplantation as a 
therapeutic option (26).
Even though liver transplantation would be expected to be 
curative for HAE, we have not been able to identify any reports 
of patients who have undergone liver transplantation either for 
HAE or for a coincidental indication. However, we have identified 
an instance where a patient developed type 1 HAE after receiving 
a liver from a donor with HAE (27). This observation is strongly 
indicative that HAE could be cured by liver transplantation.
It may be argued that patients with HAE have other effective 
treatments and therefore should not be considered for liver 
transplantation. However, the results of liver transplantation are 
continuing to improve, and alternative therapies are expensive 
and have limited availability. Use of prophylactic C1 INH can 
cost over US $200,000 per year. The costs of liver transplantation 
varies widely and certainly after the upfront cost of the surgery, 
and the annual cost of prophylactic C1 INH would exceed that 
of post liver transplantation care (Table  2). If a patient with 
HAE has a standard indication for liver transplantation, they 
should receive priority as the liver transplant may cure both 
disorders.
Auxiliary partial orthotopic liver transplantation (APOLT) 
could potentially be used in patients with type 1 HAE (28). 
This procedure carries a lower post-procedure risk than liver 
replacement because if the graft fails, the native liver is retained 
and is able to provide other essential functions. While transin-
hibition may be taking place in type 1 HAE patients’ livers, the 
graft may produce sufficient C1 INH to control the contact 
phase. This may be less effective in patients with type 2 HAE, 
where large amounts of dysfunctional C1 INH are produced 
and could outcompete the wild-type C1 INH produced by the 
graft. However, even a small change in the ratio of wild-type 
to mutant C1 INH levels may ameliorate the disorder in type 
2 HAE patients as seen with androgen treatment. As discussed 
below, C1 INH could be given by regular subcutaneous infusion 
and functional C1 INH levels could be measured to determine 
the threshold at which symptoms are ameliorated. This may 
allow better selection of patients for some of the interventions 
proposed here.
Hepatocyte transplantation is another potential approach. 
Here, individual hepatocytes are isolated from the donor liver 
(29) and then infused into the recipients’ livers via either the 
portal vein or the umbilical vein or peritoneum in neonates. 
Engrafted hepatocytes would be expected to produce proteins 
including C1 INH. Again, this option may be more effective in 
patients with type 1 HAE than those with type 2 HAE. Although 
hepatocyte transplantation has been undertaken for a variety 
of metabolic liver diseases, there are still significant barriers to 
long-term engraftment and hepatocyte transplantation remains 
an experimental procedure (29). Hepatocyte transplantation 
also requires immunosuppression, and some hepatocytes may 
dedifferentiate and cease to produce proteins, leading to eventual 
therapeutic failure (29).
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Recent advances in tissue engineering such as use of decel-
lularized organ matrices and 3D printing may pave the way 
to new alternatives in treating liver diseases (30). Technical 
advances would be needed before this procedure becomes a 
routine treatment for HAE. The risks of long-term immuno-
suppression need to be balanced against availability of effective 
drugs to treat HAE.
Liver-bAseD GeNe tHerAPies
Two decades ago, there was considerable interest in liver gene 
therapy (31). In most trials, a vector, usually an Adenovirus, car-
rying a wild-type copy of the defective gene was introduced into 
hepatocytes. The wild-type protein was expressed in the cells to 
rectify the defective gene. Non-integrating vectors with the wild-
type gene insert do not integrate into the host genome; hence, 
permanent and controllable gene expression was problematic.
The vector manipulation was able to be undertaken ex vivo or 
in vivo. An ex vivo gene therapy protocol was trialed in patients 
with type 2 familial hypercholesterolemia (32). Hepatocytes 
were isolated from the resected left lateral lobe, cultured, and 
genetically modified. The transgenic hepatocytes were then 
transplanted back to the patients. The treatment led to modest 
decrease in the LDL cholesterol. This strategy was hampered 
by technical difficulties with the genetic manipulation and the 
low number of transplanted hepatocytes which successfully 
integrated in vivo (33).
In other liver-based gene therapies, the recombinant virus 
was infused into the patient after being prepared in  vitro. The 
virus infected the target cells and subsequently the host cell 
machinery produced the therapeutic protein. Enthusiasm for this 
strategy was seriously dampened after the death of 18-year-old 
Jesse Gelsinger, a patient with mild ornithine transcarbamoylase 
(OTC) deficiency. Jesse was a mosaic for OTC and had a mild 
disorder. He was enrolled in an Adenovirus gene therapy trial at 
the University of Pennsylvania. Within 3 days of gene therapy, he 
had a catastrophic immune response to the adenoviral vector and 
died of multi organ failure (34). A subsequent FDA investigation 
uncovered protocol issues as well as potential conflicts of interest 
(35). A lawsuit was settled out of court. The chief investigator has 
courageously shared his insights into the tragedy for the benefit of 
future participants and investigators in such trials (36).
Subsequently, trials of adeno-associated viral (AAV) vectors 
have proved safer and more effective (37). This group of parvovi-
ruses is commonly found in humans and is non-pathogenic. The 
AAV vector does not elicit an intense antiviral immune response. 
It is therefore considerably less immunogenic than the previ-
ous Adenoviral vectors. Patients with hemophilia B have been 
successfully treated with this approach with long-term improve-
ment in bleeding diathesis. A 1–5% increase in FIX production 
has been sufficient to ameliorate bleeding. A number of AAV/
hemophilia B trials are currently in progress (38, 39). In these 
studies, F12 cDNA (1.4 kbp) was incorporated, packaged into an 
AAV8 vector, and infused into patients.
Similarly, C1-INH cDNA (1.5  kbp) could potentially be 
delivered into patients via an AAV8 vector. It is possible that 
even an increase of 5% wild-type C1 INH expression may 
modify the angioedema tendency of type 1 HAE patients, as 
has been achieved in FIX deficiency. This is similar to quantities 
that would be expected with androgen therapy. Recent studies 
have shown that maintaining functional C1 INH levels above 
40% prevents angioedema attacks (23). It may be possible to 
achieve this with liver-based gene therapy. Perhaps, patients 
could be selected based on their baseline functional C1 INH 
levels. Patients who are most likely to benefit may be those 
with functional C1 INH levels of 20–30%. As suggested above, 
these patients could be given a trial of subcutaneous C1 INH 
to confirm that levels >40% result in reliable suppression of 
angioedema attacks (23).
Although the AAV vector is considerably less immunogenic 
than the previous Adenoviral vectors, it can still provoke an 
immune response leading to elimination of transfected cells (40). 
Furthermore, previous exposure to AAV can result in forma-
tion of neutralizing antibodies, which may impair the efficacy 
of the AAV-mediated gene transfer. A late T cell response can 
also lead to elimination of transfected hepatocytes and provoke 
a transient hepatitis. Some protocols use immunosuppression 
at the time of vector infusion to impede the immune response. 
Immunosuppressive drugs carry severe long-term risks including 
permanent immunosuppression and will need to be used with 
caution.
Efforts are underway to further reduce the immunogenicity 
of the vector by modifying or deleting other viral proteins (41). 
An alternative approach is the isolation and modification of 
endogenous AAVs, which have already infected patients and use 
these as customized vectors. These viruses are likely to be seen 
as self and are unlikely to provoke a severe T or B cell response. 
These “stealth” virus vectors may prove safe and efficacious but 
will involve considerable expense as each patient would require 
creation of their own customized vector. Immunosuppression 
may not be needed with this approach.
There is considerable interest in other new viral and non-viral 
approaches for gene therapy in liver disease (31). Most human 
studies are at a proof-of-concept stage. Again, the use of this 
technology will need to be balanced with the effective drugs 
currently available for HAE. AAV gene therapy for Hemophilia 
B was recently approved by the FDA, underscoring the potential 
of these approaches.
Animal studies will be needed to ensure that overexpres-
sion of the C1 INH does not cause problems with the contact, 
fibrinolytic, or complement systems. This would seem unlikely 
given that many patients are now on long-term prophylactic C1 
INH treatment and do not suffer adverse effects in other systems. 
Furthermore, overexpression of transfected genes has not been 
seen any liver-based gene therapy trial to date and is unlikely to 
be a clinical problem.
IN VIVO GeNe eDitiNG iNcLUDiNG tHe 
crisPr cas9 sYsteM
The ultimate goal of gene therapy is to enable long-term expres-
sion of the corrected gene under the control of endogenous 
regulatory elements to cure the disorder. The newest frontier of 
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gene therapy is in  vivo genome editing. This technique allows 
researchers to carry out site specific modification of the host 
genome. Numerous papers have reported encouraging results 
from cellular and murine studies (42).
The concept of clustered, regularly interspaced, short palin-
dromic repeat (CRISPR)-mediated genome editing originates 
from the bacterial adaptive defense system against bacteriophage 
attack. CRISPRs in bacterial genomes consist of sequences of 
viral origin (43). In this system, bacteriophage sequences have 
been incorporated into bacterial genomes. When attacked by 
bacteriophages, bacteria are able to transcribe these sequences 
which then hybridize to the phage nucleic acids. The Cas series of 
enzymes are then able to degrade the phage DNA.
This system has been adapted for modifying genomes of 
eukaryotic cells (43, 44). With the use of guide RNAs, mam-
malian sequences can be targeted and edited. By editing 
target genes, mutations can be corrected in  vivo. Hereditary 
tyrosinemia caused by fah mutations has been corrected in 
mice with a vector bearing the wild-type gene and the Cas9 
enzyme (45). Even a slight change in ratio of wild type: mutant 
transcripts may alter the phenotype leading to a milder version 
of HAE. In hepatocytes where the mutation has been corrected, 
transinhibition will no longer apply, which may lead to a dis-
proportionate increase in wild-type C1 INH transcripts and 
protein. This is supported by an interesting observation, where 
HAE type 1 was corrected by bone marrow transplantation. The 
amount of C1 INH produced by the transplanted macrophages 
is likely to be minor compared with that produced in the liver. 
This observation supports the notion that even a small increase 
in wild-type C1 INH by any method may alter the phenotype 
of the patient (46).
Other gene-editing methods have also been trialed. A proof-
of-concept study was recently published where the CCR5 gene 
in CD4 cells from HIV patients was modified with a Zn finger 
nuclease to prevent HIV infection (47). CCR5 is a co-receptor for 
HIV entry into CD4 cells, and mutations can confer resistance to 
HIV (48). In this uncontrolled study, there was a rapid increase 
in CD4 cells and a corresponding reduction in HIV viral load. 
Zn finger nucleases offer an alternative method to CRISPR Cas9 
for gene editing.
Perhaps, a combination of an AAV carrier with a plasmid car-
rying the CRISPR Cas9 or Zn finger nuclease may prove effective 
in the future for some HAE patients. Promising developments 
have been reported in the animal literature. Zinc finger nucleases, 
delivered as part of the AAV viral package via the tail vein, have 
been shown to deliver target genes to the liver leading to gene 
correction in a hemophilia B mouse model.
A screening study identified Cas9 from Staphylococcus 
aureus (SaCas9), which exhibits similar DNA editing efficiency 
to the present system with S. pyogenes Cas9 (SpCas9) (49). 
SaCas9 is 25% smaller than SpCas9 and could be packaged 
more efficiently into the AAV viral capsule. Ran et al. used the 
SaCas9/AVV to target cholesterol regulatory gene Pcsk9 in the 
mouse liver (49). They reported a reduction in serum Pcsk9 and 
cholesterol levels.
Although gene editing shows great promise for treating 
patients with genetic disorders (50), serious technical issues may 
limit the safe, widespread application of the technology. In the 
CRISPR Cas9 system, the guide RNA is critical in preventing off-
target effects. In this system, it may be difficult to detect off-target 
effects in all modified cells. Even a single aberrantly gene-edited 
cell could clonally expand and give rise to malignancy, akin to 
previous gene therapy studies in SCIDX1 patients (51). A recent 
study of gene editing of non-viable human embryos showed a 
high incidence of off-target effects (52).
Furthermore, there may be a risk of immunological reactions 
against the Cas9 nuclease. There may be a risk of transient or 
chronic hepatitis. Currently, this technology can only be applied 
to small mutations. Complex rearrangements including large 
deletions and inversions cannot be corrected with the CRISPR 
Cas9 system at this time. Up to 20% of patients with type 1 and 
type 2 HAE have complex mutations that would not be amenable 
to current gene-editing techniques.
Other approaches may, however, be useful when there are 
complex gene rearrangements, such as those seen in the 20% of 
HAE patients with complex mutations. Chromosomal inver-
sion in factor VIII (F8) causes almost half of all severe hemo-
philia A. Park et al. reported using transcription activator-like 
effector nucleases (TALEN) to revert an inverted 140  kbp 
mutation to its original orientation in human-induced pluri-
potent stem cells (iPSCs). The approach also restores FVIII 
mRNA production (53).
The efficiency of gene editing may also be a problem for 
patients with HAE. In the case of hereditary tyrosinemia and 
HIV, the gene correction frequency was low, but the gene-edited 
cells had a proliferative/survival advantage. This may not be the 
case in HAE. However, as shown above, a small number of gene-
corrected cells may be sufficient to ameliorate the angioedema 
phenotype.
The serious safety issues of in  vivo gene editing will need 
to be addressed. Strategies for mutation correction with high 
efficiency but zero risk of off-target effects are unlikely to be 
established in the immediate future. This technology will have to 
overcome major technical and safety barriers before it could be 
used routinely for correcting genetic defects in human diseases. 
It would seem most prudent to initially trial these technologies in 
otherwise lethal diseases, for which there is no current treatment, 
rather than HAE.
HAe PreveNtiON
In addition to the technologies discussed above, prevention of 
HAE is possible with prenatal diagnosis and preimplantation 
genetic diagnosis (PGD) (54). The genetic diagnosis must be 
established before considering these options (55–57). Patients 
must undergo intensive counseling before these options are 
considered. The possibility of having mildly affected progeny and 
the stress associated with in vitro fertilization must be considered 
prior to PGD. Female patients with HAE may be vulnerable to 
angioedema attacks during hormonal stimulation in the egg 
harvesting phase of IVF and will need prophylactic C1 INH. 
Given that 25% of patients are the result of new mutations, this 
strategy will not prevent all cases of HAE. Furthermore, in some 
patients, the mutation cannot be identified, and this will also limit 
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the numbers of patients who could be offered prenatal diagnosis 
and/or PGD.
cONcLUsiON
In the future, safe, cheap, and effective oral treatments may 
become available for patients with HAE. Apart from oral andro-
gens, with their well-recognized adverse effects, most other 
prophylactic treatments are prohibitively expensive for most 
countries (Table 1). Regarding HAE as a metabolic liver disorder 
may facilitate new therapeutic approaches to prevent or cure the 
disorder (Table 2; Figure 1). Elucidating the basis of transinhibi-
tion will be the key to understanding the molecular pathology 
of HAE. There may be a range of curative options available to 
physicians in the future. These options are likely to depend on the 
nature of the mutation in individual HAE patients. Clearly, much 
more research is needed before these technologies can be safely 
offered clinically. Given the lessons of the past, we suggest these 
options are deployed with great caution.
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